ProtoKinetix SEC Filings

Type
Report
Date
D/AD/A-Formular12/23/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/21/2025
8-K/A8-K/A-Formular11/19/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/17/2025
10-QQuartalsbericht11/13/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/10/2025
DD-Formular10/2/2025
DEF 14ADEF 14A-Formular9/15/2025
PRE 14APRE 14A-Formular9/5/2025
10-QQuartalsbericht8/13/2025
D/AD/A-Formular8/12/2025
10-QQuartalsbericht5/15/2025
D/AD/A-Formular5/14/2025
10-KJahresbericht3/28/2025
DD-Formular3/27/2025
D/AD/A-Formular1/21/2025
D/AD/A-Formular11/25/2024
10-QQuartalsbericht11/12/2024
4Insidertransaktion9/27/2024
10-QQuartalsbericht7/30/2024
D/AD/A-Formular6/27/2024
SC 13D/ASC 13D/A-Formular6/17/2024
4Insidertransaktion6/17/2024
D/AD/A-Formular5/15/2024
10-QQuartalsbericht5/15/2024
D/AD/A-Formular4/18/2024
DD-Formular4/16/2024
4Insidertransaktion4/15/2024
10-KJahresbericht3/20/2024
DD-Formular12/28/2023
SC 13D/ASC 13D/A-Formular12/28/2023
4Insidertransaktion12/28/2023
4Insidertransaktion10/27/2023
10-QQuartalsbericht10/18/2023
D/AD/A-Formular9/7/2023
4Insidertransaktion8/30/2023
10-QQuartalsbericht7/14/2023
D/AD/A-Formular6/16/2023
SC 13D/ASC 13D/A-Formular6/15/2023
4Insidertransaktion6/15/2023
D/AD/A-Formular5/25/2023
4Insidertransaktion5/24/2023
10-QQuartalsbericht5/2/2023
10-KJahresbericht3/17/2023
SC 13D/ASC 13D/A-Formular2/15/2023
SC 13G/ABeneficial ownership report2/15/2023
SC 13G/ABeneficial ownership report2/15/2023
D/AD/A-Formular2/7/2023
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/1/2023
4Insidertransaktion1/31/2023
DD-Formular1/6/2023
4Insidertransaktion1/4/2023
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/4/2023
DD-Formular12/23/2022
4Insidertransaktion12/14/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/13/2022
4Insidertransaktion12/9/2022
4Insidertransaktion12/9/2022
4Insidertransaktion12/9/2022
4Insidertransaktion12/9/2022
10-QQuartalsbericht10/31/2022
D/AD/A-Formular10/14/2022
4Insidertransaktion10/11/2022
10-QQuartalsbericht7/29/2022
DD-Formular7/26/2022
4Insidertransaktion7/14/2022
D/AD/A-Formular5/18/2022
4Insidertransaktion5/18/2022
10-QQuartalsbericht5/10/2022
4Insidertransaktion4/14/2022
DD-Formular4/1/2022
SC 13D/ASC 13D/A-Formular3/21/2022
SC 13G/ABeneficial ownership report3/21/2022
SC 13G/ABeneficial ownership report3/21/2022
4Insidertransaktion3/21/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/21/2022
4Insidertransaktion3/17/2022
4Insidertransaktion3/17/2022
4Insidertransaktion3/17/2022
4Insidertransaktion3/17/2022
10-KJahresbericht3/10/2022
D/AD/A-Formular2/25/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/14/2022
DEFA14ADEFA14A-Formular2/11/2022
DEFA14ADEFA14A-Formular1/14/2022
D/AD/A-Formular1/12/2022
DEF 14ADEF 14A-Formular12/30/2021
DEFA14ADEFA14A-Formular12/30/2021
DD-Formular12/28/2021
4Insidertransaktion12/28/2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/23/2021
PRE 14APRE 14A-Formular12/20/2021
DD-Formular12/10/2021
10-QQuartalsbericht11/12/2021
D/AD/A-Formular10/8/2021
DD-Formular9/21/2021
4Insidertransaktion9/2/2021
4Insidertransaktion8/6/2021
SC 13G/ABeneficial ownership report8/6/2021
SC 13G/ABeneficial ownership report8/6/2021

ProtoKinetix Documents 2026

This page contains all official documents and SEC filings for ProtoKinetix stock (PKTX, ISIN: US7437221002). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of ProtoKinetix's regulatory filings.

ProtoKinetix Stock analysis

ProtoKinetix ProtoKinetix Inc. is a Canadian biotechnology company focused on the development of glycoproteins for therapeutic applications. The company was founded in 2005 and is headquartered in Marietta, USA. ProtoKinetix specializes in the research and development of AAGP® (Anti-Aging Glycopeptide) as biopharmaceuticals. These proprietary glycoproteins have the ability to protect cells and can be used in various therapeutic applications for improving damage in physical injury, spinal cord injury, diabetes, transplantation, and retinal diseases. In addition to the medical field, ProtoKinetix is also developing its patented technology for use in bio-agriculture and animal healthcare. It has a subsidiary that holds the rights to use and distribute AAGP® and its patents. ProtoKinetix's business model involves licensing its glycoprotein technology for various applications, including biopharmaceuticals, bioprocessing industries, and cell protection management for regenerative medicine and stem cell preparations. The company has established partnerships with other biotech companies to integrate its AAGP® technology into their product pipelines. ProtoKinetix's flagship product is the AAGP® protein solution, which is used as a medication in regenerative medicine, organ transplantation, eye healing, and animal health. It is also interested in researching the application of AAGP® in crop farming to increase yields and improve soil quality. ProtoKinetix is poised to play a significant role in the development of glycoproteins as future medicines and therapeutic technologies in various industries. It not only has the potential to explore healing medical products but also aims to enhance agriculture and animal care. ProtoKinetix represents an excellent example of a biotechnology company focused on improving the healthcare and agricultural industries.